While the direct antitumor application has not succeeded yet, several Wnt/β-catenin signaling inhibitors show the potential for enhanced immunotherapy [39, 40], likely due to their capability to remodel tumor immune microenvironment, especially promoting DCs infiltration by recovering the excretion of CCL4. This evidence concerns the gene CCL4 and neoplasm.